-
Mashup Score: 11No Benefit for Extended Lymph Node Surgery in MIBC - 17 day(s) ago
In people with localized muscle-invasive bladder cancer (MIBC), extended lymph node surgery doesn’t help them live longer, a large clinical trial found.
Source: www.cancer.govCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 2
PURPOSEAlterations in DNA damage response (DDR) genes, including ERCC2, have been correlated with response to neoadjuvant cisplatin-based chemotherapy (NAC) in patients with muscle-invasive bladder cancer (MIBC). The SWOG 1314 (S1314) trial enrolled …DDR gene alterations associate with neoadjuvant chemosensitivity in muscle-invasive bladder cancer
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
DNA Damage Response Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial | JCO Precision Oncology https://t.co/x5pRYXkiMW
-
-
Mashup Score: 6Lung-MAP 3.0: The Next Generation | SWOG - 22 day(s) ago
Originally limited to patients with squamous cell lung cancer, in 2019 the trial expanded to include all histologies (Lung-MAP 2.0). Over its 10 years, it has activated 19 sub-studies, testing numerous new treatments, and has provided genomic testing for thousands of patients who otherwise would not have had it.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair blog: Lung-MAP 3.0: The Next Generation The latest revision of the @LungMAP master protocol greatly expands the options for next-generation sequencing testing that can be used for matching patients to the trial's sub-studies in #NSCLC. https://t.co/OiUmxAF18t https://t.co/QShqn8lboE
-
-
Mashup Score: 1
Immuno-oncology has transformed the treatment of cancer, with several immunotherapies becoming the standard treatment across histologies. Despite these advancements, the majority of patients do not experience durable clinical benefits, highlighting the imperative for ongoing advancement in immuno-oncology. Computational immuno-oncology emerges as a forefront discipline that draws on biomedical data science and intersects with oncology, immunology, and clinical research, with the overarching goal to accelerate the development of effective and safe immuno-oncology treatments from the laboratory to the clinic. In this review, we outline 10 critical challenges and opportunities in computational immuno-oncology, emphasizing the importance of robust computational strategies and interdisciplinary collaborations amid the constantly evolving interplay between clinical needs and technological innovation.
Source: jitc.bmj.comCategories: General Medicine News, Onc News and JournalsTweet-
Our #TranslationalMedicine link of the week, chosen by @SWOG's @recnac1 & Jimmy Rae, PhD: Ten Challenges and Opportunities in Computational Immuno-Oncology https://t.co/f8dqw8WfK3 https://t.co/XHy6P9zExQ
-
-
Mashup Score: 18
Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
The @theNCI’s #myeloMATCH portfolio of precision medicine trials in #myeloid cancers is now open at 150 treatment sites across the US & Canada, & growing. #leukemia #myelodysplastic #leusm #MDSsm #bmtsm #AMLsm @Alliance_org @CDNCancerTrials @eaonc @SWOG https://t.co/zrDYIQS7Sr https://t.co/Nigo2ziTym
-
-
Mashup Score: 6Wrapping Up the Chicago Meeting (and So Much More!) | SWOG - 29 day(s) ago
Changing practice in Hodgkin lymphoma
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Our @SWOGChair's blog: Wrapping Up the Chicago Meeting (and So Much More!) Our group meeting in Chicago was the main event in a busy couple of weeks for @SWOG. https://t.co/gdsBB2b3xX https://t.co/S6wWR1XrKk
-
-
Mashup Score: 18
Four leading cancer research organizations in the United States and Canada announce the opening of patient enrollment to myeloMATCH, a unique portfolio of clinical trials to test precision medicine treatments for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
The @theNCI’s #myeloMATCH portfolio of precision medicine trials in #myeloid cancers is now open at 150 treatment sites across the US & Canada, & growing. #leukemia #myelodysplastic #leusm #MDSsm #bmtsm #AMLsm @Alliance_org @CDNCancerTrials @eaonc @SWOG https://t.co/zrDYIQS7Sr https://t.co/Nigo2ziTym
-
-
Mashup Score: 10S1826 data confirm nivo-AVD benefit in Hodgkin lymphoma | SWOG - 1 month(s) ago
In mid-2023, the SWOG S1826 phase 3 trial in advanced Hodgkin lymphoma reported highly positive primary results earlier than expected, after the trial’s second planned interim analysis found the preset threshold for efficacy had already been reached.
Source: www.swog.orgCategories: General Medicine News, Oncologists1Tweet-
Gives a whole new meaning to "let them eat cake"! Congratulations @DrJFriedberg, Drs. Alex Herrera and Michael LeBlanc, and the many, many others who contributed to this huge advance for those facing #Hodgkins #lymphoma. Read more: https://t.co/uy1VxTiaOo https://t.co/YqxHwcq0AG
-
-
Mashup Score: 1Breakthrough Clinical Trial Reveals Better Treatment for Advanced Classic Hodgkin Lymphoma - 1 month(s) ago
Updated results from a phase 3 clinical trial co-developed by Roswell Park’s Dr. Kara Kelly are expected to change the way advanced stage classic Hodgkin lymphoma (cHL) is treated in newly diagnosed adolescents and adults. Details appear in a study published today in The New England Journal of Medicine.
Source: www.roswellpark.orgCategories: General Medicine News, Oncologists1Tweet-
RT @RoswellPark: Learn more about this pivotal breakthrough! 🔗: https://t.co/poD2rdLJLo
-
-
Mashup Score: 37Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma | NEJM - 1 month(s) ago
Incorporating brentuximab vedotin into the treatment of advanced-stage classic Hodgkin’s lymphoma improves outcomes in adult and pediatric patients. However, brentuximab vedotin increases the toxic…
Source: www.nejm.orgCategories: General Medicine News, Oncologists1Tweet-
Nivo+AVD led to longer progression-free survival than standard BV+AVD in adolescents & adults with stage III or IV advanced-stage classic Hodgkin lymphoma & had a better side-effect profile. Results of @SWOG @COGorg S1826 in @NEJM. @DrJFriedberg @theNCI https://t.co/9vaTJVP3fg
-
From @theNCI Cancer Currents blog, an update on results of the @SWOG S1011 trial, which found extended lymph node removal in surgery for bladder cancer does not improve survival (results published in the Oct 3, 2024 @NEJM): https://t.co/wRlt2FbeCA @slernerbcmedu1 @PrimoLaraMD https://t.co/eWxRloYmsQ